Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

Summary

That anti-TNF therapy and rituximab therapy are equally effective in treating patients with rheumatoid arthritis who meet the eligibility criteria for biologic therapy in the British Society for Rheumatology guidelines, and have not previously been exposed to biologic therapy.

Timeline

Start

2010-04

Primary completion

2014-12

Completion

2015-04

Outcome

Met primary endpoint

paper with a difference within the prespecified non-inferiority margin of -0.19 (95% CI -0.51 to 0.13; p=0.24). PMID 27197690 ↗

Publications

• Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016 Jul 16;388(10041):239-47. doi: 10.1016/S0140-6736(16)00380-9. Epub 2016 May 17.

Drugs

Indications